Table 3: Response to maximal intra-arterial doses of vasodilators in diabetics and controls with DHEA versus placebo
Vasodilator |
P-value |
||
|
Percent increase in blood flow from baseline ± SD |
|||
|
DHEA |
Placebo |
||
|
Diabetics |
|||
|
NTP 10 μg/min |
317.6 ± 87.9 |
364.8 ± 98.3 |
0.30 |
|
ACH 100 μg/min |
413.7 ± 156.8 |
479.5 ± 118.2 |
0.30 |
|
VER 300 μg/min |
449.0 ± 169.7 |
462.2 ± 77.5 |
0.60 |
|
Controls |
|||
|
NTP 10 μg/min |
277.8 ± 117.3 |
275.5 ± 66.7 |
0.70 |
|
ACH 100 μg/min |
342.8 ± 148.6 |
334.0 ± 108.6 |
1.00 |
|
VER 300 μg/min |
323.1 ± 69.7 |
356.6 ± 54.2 |
0.70 |